Learning About the Gut- Liver Axis as a Therapeutic Target in NASH

Time: 1:30 pm
day: Day 1 Stream 1 PM


• Describing the importance of the microbiome in health and disease
• Exploring possible mechanisms by which changes in the microbiome may improve NASH
• Understanding the effects of HTD1801 on human NASH – possible actions via microbiome Adrian M. Di Bisceglie, Chief Medical Officer, HighTide Therapeutics